Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Krystal Biotech, Inc. (KRYS : NSDQ)
 
 • Company Description   
Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

Number of Employees: 275

 
 • Price / Volume Information   
Yesterday's Closing Price: $137.46 Daily Weekly Monthly
20 Day Moving Average: 375,644 shares
Shares Outstanding: 28.90 (millions)
Market Capitalization: $3,972.41 (millions)
Beta: 0.67
52 Week High: $219.34
52 Week Low: $122.80
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.65% 4.90%
12 Week -17.20% -32.45%
Year To Date -12.26% -16.83%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2100 WHARTON STREET SUITE 701
-
PITTSBURGH,PA 15203
USA
ph: 412-586-5830
fax: -
investors@krystalbio.com http://www.krystalbio.com
 
 • General Corporate Information   
Officers
Krish S. Krishnan - Chief Executive Officer and President
Suma M. Krishnan - President
Kathryn A. Romano - Chief Accounting Officer
Daniel S. Janney - Director
Dino A. Rossi - Director

Peer Information
Krystal Biotech, Inc. (CORR.)
Krystal Biotech, Inc. (RSPI)
Krystal Biotech, Inc. (CGXP)
Krystal Biotech, Inc. (BGEN)
Krystal Biotech, Inc. (GTBP)
Krystal Biotech, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 501147102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
Share - Related Items
Shares Outstanding: 28.90
Most Recent Split Date: (:1)
Beta: 0.67
Market Capitalization: $3,972.41 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $1.31 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $5.70 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 24.13
Trailing 12 Months: 30.61
PEG Ratio: -
Price Ratios
Price/Book: 4.03
Price/Cash Flow: 29.64
Price / Sales: 11.91
EPS Growth
vs. Year Ago Period: 3,900.00%
vs. Previous Quarter: -21.05%
Sales Growth
vs. Year Ago Period: 94.88%
vs. Previous Quarter: -3.24%
ROE
06/30/25 - -
03/31/25 - 14.64
12/31/24 - 11.41
ROA
06/30/25 - -
03/31/25 - 13.28
12/31/24 - 10.40
Current Ratio
06/30/25 - -
03/31/25 - 9.65
12/31/24 - 7.28
Quick Ratio
06/30/25 - -
03/31/25 - 9.27
12/31/24 - 7.02
Operating Margin
06/30/25 - -
03/31/25 - 40.14
12/31/24 - 34.09
Net Margin
06/30/25 - -
03/31/25 - 37.17
12/31/24 - 30.69
Pre-Tax Margin
06/30/25 - -
03/31/25 - 41.39
12/31/24 - 32.82
Book Value
06/30/25 - -
03/31/25 - 34.07
12/31/24 - 32.90
Inventory Turnover
06/30/25 - -
03/31/25 - 1.04
12/31/24 - 1.17
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©